References

• 1. 1)
     • 14. Horvath, A., Pakala, S.B., Mudvari, P., et al: ‘Novel insights into breast cancer genetic variance through RNA sequencing’, Sci. Rep., 2013, 3, p. 2256.
  2. 2)
     • 27. Xu, X., Hou, Y., Yin, X., et al: ‘Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor’, Cell, 2012, 148, pp. 886–895.
  3. 3)
     • 67. Howlader, N., Noone, A., Krapcho, M., et al: ‘Cancer statistics review, 1975–2011’ (National Cancer Institute, Bethesda, MD, 2014).
  4. 4)
     • 45. Kitzman, J.O., Snyder, M.W., Ventura, M., et al: ‘Noninvasive whole-genome sequencing of a human fetus’, Sci. Transl. Med., 2012, 4, (137), pp. 137ra76–137ra76.
  5. 5)
     • 65. Antoniou, A., Pharoah, P., Narod, S., et al: ‘Average risks of breast and ovarian cancer associated with brca1 or brca2 mutations detected in case series unselected for family history: a combined analysis of 22 studies’, Am. J. Human Genet., 2003, 72, (5), pp. 1117–1130.
  6. 6)
     • 23. Shen, L., Kondo, Y., Rosner, G.L., et al: ‘Mgmt promoter methylation and field defect in sporadic colorectal cancer’, J. Natl. Cancer Inst., 2005, 97, (18), pp. 1330–1338.
  7. 7)
     • 8. Metzker, M.L.: ‘Sequencing technologiesthe next generation’, Nat. Rev. Genet., 2010, 11, (1), pp. 31–46.
  8. 8)
     • 12. Li, B., Ruotti, V., Stewart, R.M., et al: ‘Rna-seq gene expression estimation with read mapping uncertainty’, Bioinformatics, 2010, 26, (4), pp. 493–500.
  9. 9)
     • 13. Jiang, L., Schlesinger, F., Davis, C.A., et al: ‘Synthetic spike-in standards for RNA-seq experiments’, Genome Res., 2011, 21, pp. 1543–1551.
  10. 10)
      • 28. Du, W., Elemento, O.: ‘Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies’, Oncogene, 2015, 34, pp. 3215–3225.
  11. 11)
      • 74. Hantash, F.M., Olson, S.C., Anderson, B., et al: ‘Rapid one-step carrier detection assay of mucolipidosis IV mutations in the Ashkenazi Jewish population’, J. Mol. Diagn., 2006, 8, pp. 282–287.
  12. 12)
      • 90. Yamanaka, R.: ‘Cell- and peptide-based immunotherapeutic approaches for glioma’, Trends Mol. Med., 2008, 14, pp. 228–235.
  13. 13)
      • 16. ONeill, L.P., Turner, B.M.: ‘Immunoprecipitation of native chromatin: Nchip’, Methods, 2003, 31, (1), pp. 76–82.
  14. 14)
      • 95. Brentjens, R.J., Davila, M.L., Riviere, I., et al: ‘Cd19-targeted t cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia’, Sci. Transl. Med., 2013, 5, (177), pp. 177ra38–177ra38.
  15. 15)
      • 89. G. M.-a. T. G. Group: ‘Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials’, Lancet, 2002, 359, (9311), pp. 1011–1018.
  16. 16)
      • 82. Schnitt, S.J.: ‘Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy’, Mod. Pathol., 2010, 23, pp. S60–S64.
  17. 17)
      • 31. Ong, S.-E., Blagoev, B., Kratchmarova, I., et al: ‘Stable isotope labeling by amino acids in cell culture, silac, as a simple and accurate approach to expression proteomics’, Mol. Cell. Proteomics, 2002, 1, (5), pp. 376–386.
  18. 18)
      • 33. Qiu, P., Simonds, E.F., Bendall, S.C., et al: ‘Extracting a cellular hierarchy from highdimensional cytometry data with spade’, Nat. Biotechnol., 2011, 29, (10), pp. 886–891.
  19. 19)
      • 81. Issa, J.-P.J., Ottaviano, Y.L., Celano, P., et al: ‘Methylation of the oestrogen receptor cpg island links ageing and neoplasia in human colon’, Nat. Genet., 1994, 7, (4), pp. 536–540.
  20. 20)
      • 83. Nielsen, D.L., Kümler, I., Palshof, J.A., et al: ‘Efficacy of her2-targeted therapy in metastatic breast cancer. monoclonal antibodies and tyrosine kinase inhibitors’, Breast, 2013, 22, (1), pp. 1–12.
  21. 21)
      • 35. Behbehani, G.K., Bendall, S.C., Clutter, M.R., et al: ‘Single-cell mass cytometry adapted to measurements of the cell cycle’, Cytometry A, 2012, 81, (7), pp. 552–566.
  22. 22)
      • 30. Wei, X., Li, L.: ‘Mass spectrometry-based proteomics and peptidomics for biomarker discovery in neurodegenerative diseases’, Int. J. Clin. Exp. Pathol., 2009, 2, (2), pp. 132–148.
  23. 23)
      • 47. Chan, K.C.A., Zhang, J., Hui, A.B.Y., et al: ‘Size distributions of maternal and fetal DNA in maternal plasma’, Clin. Chem., 2004, 50, pp. 88–92.
  24. 24)
      • 1. Venter, J.C., Adams, M.D., Myers, E.W., et al: ‘The sequence of the human genome’, Science, 2001, 291, (5507), pp. 1304–1351.
  25. 25)
      • 78. A.C. Society: ‘American cancer society breast cancer facts & figures’. Breast Cancer Facts and Figures, 2015, pp. 1–38.
  26. 26)
      • 39. Bianchi, D.W., Simpson, J., Jackson, L., et al: ‘Fetal gender and aneuploidy detection using fetal cells in maternal blood: analysis of nifty i data’, Prenat. Diagn., 2002, 22, (7), pp. 609–615.
  27. 27)
      • 46. Hill, M., Barrett, A.N., White, H., et al: ‘Uses of cell free fetal dna in maternal circulation’, Best Pract. Res. Clin. Obstet. Gynaecol., 2012, 26, (5), pp. 639–654.
  28. 28)
      • 73. Bach, G.: ‘Mucolipidosis type IV’, Mol. Genet. Metab., 2001, 73, pp. 197–203.
  29. 29)
      • 38. Schlütter, J.M., Kirkegaard, I., Petersen, O.B., et al: ‘Fetal gender and several cytokines are associated with the number of fetal cells in maternal blood–an observational study’, PloS One, 2014, 9, (9), p. e106934.
  30. 30)
      • 84. Klijn, J.G., Setyono-Han, B., Foekens, J.A.: ‘Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer’, Steroids, 2000, 65, (10), pp. 825–830.
  31. 31)
      • 5. Sanger, F., Coulson, A.R.: ‘A rapid method for determining sequences in dna by primed synthesis with dna polymerase’, J. Mol. Biol., 1975, 94, (3), pp. 441–448.
  32. 32)
      • 51. Grygalewicz, B., Woroniecka, R., Rygier, J., et al: ‘Monoallelic and biallelic deletions of 13q14 in a group of cll/sll patients investigated by cgh haematological cancer and snp array (8 × 60k)’, Mol. Cytogenet., 2016, 9, (1), p. 1.
  33. 33)
      • 61. Easton, D.F., et al: ‘How many more breast cancer predisposition genes are there’, Breast Cancer Res., 1999, 1, (1), pp. 14–17.
  34. 34)
      • 50. Chan, K.A., Ding, C., Gerovassili, A., et al: ‘Hypermethylated rassf1a in maternal plasma: a universal fetal dna marker that improves the reliability of noninvasive prenatal diagnosis’, Clin. Chem., 2006, 52, (12), pp. 2211–2218.
  35. 35)
      • 6. Bentley, D.R., Balasubramanian, S., Swerdlow, H.P., et al: ‘Accurate whole human genome sequencing using reversible terminator chemistry’, Nature, 2008, 456, (7218), pp. 53–59.
  36. 36)
      • 15. Park, P.J.: ‘ChIP–seq: advantages and challenges of a maturing technology’, Nat. Rev. Genet., 2009, 10, pp. 669–680.
  37. 37)
      • 58. King, M.-C., Marks, J.H., Mandell, J.B., et al: ‘Breast and ovarian cancer risks due to inherited mutations in brca1 and brca2’, Science, 2003, 302, (5645), pp. 643–646.
  38. 38)
      • 10. Turner, E.H., Lee, C., Ng, S.B., et al: ‘Massively parallel exon capture and library-free resequencing across 16 genomes’, Nat. Methods, 2009, 6, (5), pp. 315–316.
  39. 39)
      • 85. Sommer, S., Fuqua, S.A.: ‘Estrogen receptor and breast cancer’, in ‘Seminars in cancer biology’ (Elsevier, 2001), vol. 11, pp. 339–352.
  40. 40)
      • 29. Topol, E.J.: ‘Individualized medicine from prewomb to tomb’, Cell, 2014, 157, pp. 241–253.
  41. 41)
      • 54. Strittmatter, W.J., Saunders, A.M., Schmechel, D., et al: ‘Apolipoprotein e: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial alzheimer disease’, Proc. Natl. Acad. Sci., 1993, 90, (5), pp. 1977–1981.
  42. 42)
      • 19. Issa, J.-P.: ‘Cancer prevention: epigenetics steps up to the plate’, Cancer Prev. Res., 2008, 1, pp. 219–222.
  43. 43)
      • 21. Esteller, M.: ‘CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future’, Oncogene, 2002, 21, pp. 5427–5440.
  44. 44)
      • 37. Grati, F.R.: ‘Chromosomal mosaicism in human feto-placental development: implications for prenatal diagnosis’, J. Clin. Med., 2014, 3, (3), pp. 809–837.
  45. 45)
      • 62. Holloman, W.K.: ‘Unraveling the mechanism of brca2 in homologous recombination’, Nat. Struct. Mol. Biol., 2011, 18, (7), pp. 748–754.
  46. 46)
      • 64. Antoniou, A.C., Pharoah, P.D.P., Narod, S., et al: ‘Breast and ovarian cancer risks to carriers of the BRCA1 5382insc and 185delAG and BRCA2 6174delt mutations: a combined analysis of 22 population based studies’, J. Med. Genet., 2005, 42, pp. 602–603.
  47. 47)
      • 25. Nawy, T.: ‘Single-cell sequencing’, Nat. Methods, 2014, 11, p. 18.
  48. 48)
      • 75. Waldmüller, S., Sakthivel, S., Saadi, A.V., et al: ‘Novel deletions in MYH7 and MYBPC3 identified in Indian families with familial hypertrophic cardiomyopathy’, J. Mol. Cell. Cardiol., 2003, 35, pp. 623–636.
  49. 49)
      • 48. Lo, Y.M., Zhang, J., Leung, T.N., et al: ‘Rapid clearance of fetal DNA from maternal plasma’, Am. J. Hum. Genet., 1999, 64, pp. 218–224.
  50. 50)
      • 77. Deprez, R.L., Muurling-Vlietman, J.J., Hruda, J., et al: ‘Two cases of severe neonatal hypertrophic cardiomyopathy caused by compound heterozygous mutations in the mybpc3 gene’, J. Med. Genet., 2006, 43, (10), pp. 829–832.
  51. 51)
      • 2. Rothberg, J.M., Hinz, W., Rearick, T.M., et al: ‘An integrated semiconductor device enabling non-optical genome sequencing’, Nature, 2011, 475, (7356), pp. 348–352.
  52. 52)
      • 57. Takei, N., Miyashita, A., Tsukie, T., et al: ‘Genetic association study on in and around the APOE in late-onset alzheimer disease in Japanese’, Genomics, 2009, 93, pp. 441–448.
  53. 53)
      • 18. Grunau, C., Clark, S.J., Rosenthal, A.: ‘Bisulfite genomic sequencing: systematic investigation of critical experimental parameters’, Nucleic Acids Res., 2001, 29, pp. E65–E65.
  54. 54)
      • 70. D'Argenio, V., Esposito, M.V., Telese, A., et al: ‘The molecular analysis of brca1 and brca2: Next-generation sequencing supersedes conventional approaches’, Clin. Chim. Acta, 2015, 446, pp. 221–225.
  55. 55)
      • 9. Ng, P.C., Murray, S.S., Levy, S., et al: ‘An agenda for personalized medicine’, Nature, 2009, 461, pp. 724–726.
  56. 56)
      • 59. Hall, J., Lee, M., Newman, B., et al: ‘Linkage of early-onset familial breast cancer to chromosome 17q21’, Science, 1990, 250, (4988), pp. 1684–1689.
  57. 57)
      • 20. Landan, G., Cohen, N.M., Mukamel, Z., et al: ‘Epigenetic polymorphi1sm and the stochastic formation of differentially methylated regions in normal and cancerous tissues’, Nat. Genet., 2012, 44, pp. 1207–1214.
  58. 58)
      • 71. Frebourg, T., Barbier, N., Yan, Y., et al: ‘Germ-line p53 mutations in 15 families with li-fraumeni syndrome.’, Am J. Hum. Genet., 1995, 56, (3), p. 608.
  59. 59)
      • 24. Shapiro, E., Biezuner, T., Linnarsson, S.: ‘Single-cell sequencing-based technologies will revolutionize whole-organism science’, Nat. Rev. Genet., 2013, 14, pp. 618–630.
  60. 60)
      • 72. Lang, G.A., Iwakuma, T., Suh, Y.-A., et al: ‘Gain of function of a p53 hot spot mutation in a mouse model of li-fraumeni syndrome’, Cell, 2004, 119, (6), pp. 861–872.
  61. 61)
      • 49. Lo, Y.M.D., Tsui, N.B.Y., Chiu, R.W.K., et al: ‘Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection’, Nat. Med., 2007, 13, pp. 218–223.
  62. 62)
      • 91. Yu, J.S., Wheeler, C.J., Zeltzer, P.M., et al: ‘Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial t-cell infiltration’, Cancer Res., 2001, 61, (3), pp. 842–847.
  63. 63)
      • 36. Cederholm, M., Haglund, B., Axelsson, O.: ‘Infant morbidity following amniocentesis and chorionic villus sampling for prenatal karyotyping’, BJOG: Int. J. Obstet. Gynaecol., 2005, 112, (4), pp. 394–402.
  64. 64)
      • 76. Richard, P., Charron, P., Carrier, L., et al: ‘Hypertrophic cardiomyopathy distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy’, Circulation, 2003, 107, (17), pp. 2227–2232.
  65. 65)
      • 92. Schneider, T., Gerhards, R., Kirches, E., et al: ‘Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme’, J. Neurooncol., 2001, 53, pp. 39–46.
  66. 66)
      • 40. Lo, Y.M., Corbetta, N., Chamberlain, P.F., et al: ‘Presence of fetal DNA in maternal plasma and serum’, Lancet, 1997, 350, pp. 485–487.
  67. 67)
      • 80. Barzi, A., Lenz, A.M., Labonte, M.J., et al: ‘Molecular pathways: Estrogen pathway in colorectal cancer’, Clin. Cancer Res., 2013, 19, pp. 5842–5848.
  68. 68)
      • 17. Nguyen, C.T., Weisenberger, D.J., Velicescu, M., et al: ‘Histone H3-Lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2 -deoxycytidine’, Cancer Res., 2002, 62, pp. 6456–6461.
  69. 69)
      • 42. Norwitz, E.R., Levy, B.: ‘Noninvasive prenatal testing: the future is now’, Rev. Obstet. Gynecol., 2013, 6, (2), pp. 48–62.
  70. 70)
      • 79. Manolio, T.A., Collins, F.S., Cox, N.J., et al: ‘Finding the missing heritability of complex diseases’, Nature, 2009, 461, pp. 747–753.
  71. 71)
      • 93. Palucka, K., Banchereau, J.: ‘Dendritic-cell-based therapeutic cancer vaccines’, Immunity, 2013, 39, pp. 38–48.
  72. 72)
      • 53. Sherry, S.T., Ward, M.-H., Kholodov, M., et al: ‘dbsnp: the ncbi database of genetic variation’, Nucleic Acids Res., 2001, 29, (1), pp. 308–311.
  73. 73)
      • 87. Niepel, M., Hafner, M., Pace, E.A., et al: ‘Profiles of basal and stimulated receptor signaling networks predict drug response in breast cancer lines’, Sci. Signal., 2013, 6, p. ra84.
  74. 74)
      • 60. Wooster, R., Neuhausen, S.L., Mangion, J., et al: ‘Localization of a breast cancer susceptibility gene, brca2, to chromosome 13q12-13’, Science, 1994, 265, (5181), pp. 2088–2090.
  75. 75)
      • 7. Fedurco, M., Romieu, A., Williams, S., et al: ‘Bta, a novel reagent for dna attachment on glass and efficient generation of solid-phase amplified dna colonies’, Nucleic Acids Res., 2006, 34, (3), pp. e22–e22.
  76. 76)
      • 34. Amir, E.-a.D., Davis, K.L., Tadmor, M.D., et al: ‘visne enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia’, Nat. Biotechnol., 2013, 31, (6), pp. 545–552.
  77. 77)
      • 69. Vuttariello, E., Borra, M., Calise, C., et al: ‘A new rapid methodological strategy to assess brca mutational status’, Mol. Biotechnol., 2013, 54, (3), pp. 954–960.
  78. 78)
      • 98. Stitziel, N.O., Kiezun, A., Sunyaev, S.: ‘Computational and statistical approaches to analyzing variants identified by exome sequencing’, Genome Biol., 2011, 12, (9), pp. 1–10.
  79. 79)
      • 43. Bianchi, D.W., Parsa, S., Bhatt, S., et al: ‘Fetal sex chromosome testing by maternal plasma dna sequencing: clinical laboratory experience and biology’, Obstet. Gynecol., 2015, 125, (2), pp. 375–382.
  80. 80)
      • 99. Choi, M., Shi, J., Jung, S.H., et al: ‘Attractor landscape analysis reveals feedback loops in the p53 network that control the cellular response to dna damage’, Sci. Signal, 2012, 5, (251), p. ra83.
  81. 81)
      • 4. Eid, J., Fehr, A., Gray, J., et al: ‘Real-time dna sequencing from single polymerase molecules’, Science, 2009, 323, (5910), pp. 133–138.
  82. 82)
      • 52. Atlija, M., Arranz, J.-J., Martinez-Valladares, M., et al: ‘Detection and replication of qtl underlying resistance to gastrointestinal nematodes in adult sheep using the ovine 50k snp array’, Genet. Sel. Evol., 2016, 48, (1), pp. 1–16.
  83. 83)
      • 3. Kasianowicz, J.J., Brandin, E., Branton, D., et al: ‘Characterization of individual polynucleotide molecules using a membrane channel’, Proc. Natl. Acad. Sci., 1996, 93, (24), pp. 13770–13773.
  84. 84)
      • 96. Grupp, S.A., Kalos, M., Barrett, D., et al: ‘Chimeric antigen receptor-modified t cells for acute lymphoid leukemia’, New Engl. J. Med., 2013, 368, (16), pp. 1509–1518.
  85. 85)
      • 63. Silver, D.P., Livingston, D.M.: ‘Mechanisms of brca1 tumor suppression’, Cancer Discov., 2012, 2, (8), pp. 679–684.
  86. 86)
      • 97. Majid, S., Kikuno, N., Nelles, J., et al: ‘Genistein induces the p21waf1/cip1 and p16ink4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification’, Cancer Res., 2008, 68, (8), pp. 2736–2744.
  87. 87)
      • 66. Chen, S., Parmigiani, G.: ‘Meta-analysis of brca1 and brca2 penetrance’, J. Clin. Oncol., 2007, 25, (11), pp. 1329–1333.
  88. 88)
      • 32. Bandura, D.R., Baranov, V.I., Ornatsky, O.I., et al: ‘Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry’, Anal. Chem., 2009, 81, (16), pp. 6813–6822.
  89. 89)
      • 94. Provasi, E., Genovese, P., Lombardo, A., et al: ‘Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer’, Nat. Med., 2012, 18, pp. 807–815.
  90. 90)
      • 26. Navin, N., Kendall, J., Troge, J., et al: ‘Tumour evolution inferred by single-cell sequencing’, Nature, 2011, 472, pp. 90–94.
  91. 91)
      • 56. Coon, K.D., Myers, A.J., Craig, D.W., et al: ‘A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset alzheimer's disease’, J. Clin. Psychiatry, 2007, 68, pp. 613–618.
  92. 92)
      • 88. Vallejos, C.S., Gómez, H.L., Cruz, W.R., et al: ‘Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database’, Clin. Breast Cancer, 2010, 10, (4), pp. 294–300.
  93. 93)
      • 68. Gerhardus, A., Schleberger, H., Schlegelberger, B., et al: ‘Diagnostic accuracy of methods for the detection of brca1 and brca2 mutations: a systematic review’, Eur. J. Hum. Genet., 2007, 15, (6), pp. 619–627.
  94. 94)
      • 86. Isakoff, S.J.: ‘Triple negative breast cancer: role of specific chemotherapy agents’, Cancers J. (Sudbury, Mass.), 2010, 16, (1), p. 53.
  95. 95)
      • 44. Sparks, A.B., Wang, E.T., Struble, C.A., et al: ‘Selective analysis of cell-free dna in maternal blood for evaluation of fetal trisomy’, Prenat. Diagn., 2012, 32, (1), pp. 3–9.
  96. 96)
      • 22. Shen, L., Ahuja, N., Shen, Y., et al: ‘Dna methylation and environmental exposures in human hepatocellular carcinoma’, J. Natl. Cancer Inst., 2002, 94, (10), pp. 755–761.
  97. 97)
      • 11. Wang, Z., Gerstein, M., Snyder, M.: ‘Rna-seq: a revolutionary tool for transcriptomics’, Nat. Rev. Genet., 2009, 10, (1), pp. 57–63.
  98. 98)
      • 55. Liu, C.-C., Kanekiyo, T., Xu, H., et al: ‘Apolipoprotein e and alzheimer disease: risk, mechanisms and therapy’, Nat. Rev. Neurol., 2013, 9, (2), pp. 106–118.
  99. 99)
      • 41. Chiu, R.W., Chan, K.A., Gao, Y., et al: ‘Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of dna in maternal plasma’, Proc. Natl. Acad. Sci., 2008, 105, (51), pp. 20458–20463.